Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (AAVXF) EBITDA (2024 - 2025)

Historic EBITDA for Abivax (AAVXF) over the last 2 years, with Q3 2025 value amounting to -$94.4 million.

  • Abivax's EBITDA fell 7118.88% to -$94.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.4 million, marking a year-over-year change of. This contributed to the annual value of -$184.8 million for FY2024, which is 3415.84% down from last year.
  • Abivax's EBITDA amounted to -$94.4 million in Q3 2025, which was down 7118.88% from -$52.6 million recorded in Q2 2025.
  • In the past 5 years, Abivax's EBITDA ranged from a high of -$38.0 million in Q2 2024 and a low of -$94.4 million during Q3 2025